ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Anova Innovation Limited
Anova Innovation Limited
Bristol-Myers Squibb
Lumos Pharma
Verastem, Inc.
Revolution Medicines, Inc.
UNC Lineberger Comprehensive Cancer Center
iOnctura
Engeneic Pty Limited
Lokon Pharma AB
Ascentage Pharma Group Inc.
Suzhou Transcenta Therapeutics Co., Ltd.
University Health Network, Toronto
Thomas Jefferson University
Incyte Corporation
Bristol-Myers Squibb
Ability Pharmaceuticals SL
GWT-TUD GmbH
Verastem, Inc.
Lisata Therapeutics, Inc.
Prestige Biopharma Limited
NGM Biopharmaceuticals, Inc
Precision Biologics, Inc
Esperas Pharma Inc.
InxMed (Shanghai) Co., Ltd.
Herlev Hospital
BeyondBio Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chinese PLA General Hospital
Cyteir Therapeutics, Inc.
Shanghai YingLi Pharmaceutical Co. Ltd.
BioNTech SE
University of Oxford
Harbin Medical University
Shanghai Zhongshan Hospital
State University of New York - Downstate Medical Center
Fudan University
Nagoya University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu HengRui Medicine Co., Ltd.
University of Texas Southwestern Medical Center
Barbara Ann Karmanos Cancer Institute
MedImmune LLC
Changhai Hospital
Canadian Cancer Trials Group
Barbara Ann Karmanos Cancer Institute
Hoosier Cancer Research Network
HonorHealth Research Institute
Kyntra Bio
Mereo BioPharma
Eli Lilly and Company